Klimik Journal is a pivotal publication in the fields of Infectious Diseases and Medical Microbiology, serving as a platform for researchers, clinicians, and academics to disseminate groundbreaking findings and improve health outcomes. Established in 2010 and published by DOC DESIGN INFORMATICS CO LTD, this journal is dedicated to advancing knowledge and fostering discussions around critical issues in infectious diseases and microbial research. With an ISSN of 1301-143X and an E-ISSN of 1309-1484, Klimik Journal strives to maintain high academic standards despite currently ranking in the fourth quartile in both categories according to Scopus metrics, which highlights the need for continued contributions to the field. Operating from Turkey, the journal is committed to supporting open access options, thereby ensuring wide dissemination of research findings. As it continues to bridge the gap between theory and practice, Klimik Journal is poised to become an essential resource for those looking to stay at the forefront of infectious disease research and microbiological advancements.

Infectious Microbes & Diseases, published by Lippincott Williams & Wilkins, is a premier journal dedicated to the exploration and understanding of infectious diseases, microbiology, and epidemiology. With its focused scope and robust peer-review process, the journal aims to disseminate high-quality research that contributes to advancements in the field, making it an essential resource for researchers, healthcare professionals, and students alike. Established in 2019, it has quickly gained recognition, achieving a Q3 rating in categories such as Epidemiology, Infectious Diseases, and Medical Microbiology in 2023, and ranking in the top half of its field within Scopus metrics. Although currently offered as a subscription-based journal, Infectious Microbes & Diseases significantly enriches its disciplines by inviting innovative research and critical review articles, thus playing a vital role in combating the global challenges posed by infectious diseases.

The Journal of Global Antimicrobial Resistance, published by Elsevier Scientific Ltd, is a premier open access journal dedicated to addressing the critical issue of antimicrobial resistance on a global scale. Established in 2013 and significantly gaining traction as an open access platform since 2020, this journal serves as an essential resource for researchers, healthcare professionals, and policy makers invested in immunology, microbiology, and associated fields. With an impressive impact factor reflected through its consistent ranking in the Q2 category across multiple disciplines, including Microbiology and Immunology – where it ranks #29 out of 140 in Medical Microbiology – the journal ensures high-quality peer-reviewed articles that push the boundaries of current knowledge and practice. By offering a global perspective on research trends and public health implications, the Journal of Global Antimicrobial Resistance plays a pivotal role in advancing the scientific discourse necessary to combat the rising tide of antimicrobial resistance worldwide.

Antibiotics-Basel is a prestigious multidisciplinary journal published by MDPI, dedicated to advancing the field of antibiotic research and management. Since its inception in 2012 as an Open Access publication, the journal has established itself as a vital resource for researchers and professionals, offering an accessible platform for the dissemination of innovative findings in Biochemistry, Infectious Diseases, Microbiology, and Pharmacology. With a solid impact in its category, Antibiotics-Basel holds a Q1 ranking in critical areas such as Pharmacology and Pharmacology, Toxicology and Pharmaceutics, making it an influential journal in its field. The journal publishes high-quality research articles, reviews, and communications that are essential for advancing our understanding of antibiotic mechanisms, resistance, and therapeutic applications. Researchers are invited to submit their manuscript to contribute to this growing body of knowledge and collaborate in the fight against antibiotic resistance and infectious diseases.

Journal of the Pediatric Infectious Diseases Society, published by Oxford University Press, stands as a pivotal platform for advancing knowledge in the realm of pediatric infectious diseases. With an ISSN of 2048-7193 and an E-ISSN of 2048-7207, this esteemed journal has garnered significant recognition in the academic community, achieving influential rankings such as Q1 in Pediatrics, Perinatology and Child Health and Q2 in Infectious Diseases. With converged years from 2012 to 2024, it aims to publish cutting-edge research, reviews, and clinical practices that address the challenges and innovations in the field. The journal's strong performance, reflected in its Scopus ranks (33rd percentile in Pediatrics and 97th in Infectious Diseases), underscores its impact on the global healthcare landscape. As a non-open access journal, it provides exclusive content essential for researchers, medical professionals, and students dedicated to enhancing pediatric healthcare outcomes.

INFECTIOUS DISEASES IN CLINICAL PRACTICE, published by Lippincott Williams & Wilkins, is a crucial resource in the field of infectious diseases and microbiology. With an ISSN of 1056-9103 and an E-ISSN of 1536-9943, this journal has been a platform for scholarly communication since its inception in 1992, now spanning over two decades of continuous publication. The journal primarily focuses on the latest research developments, case studies, and clinical practices relevant to infectious diseases, making it an indispensable tool for researchers, healthcare professionals, and students alike. Although it is currently categorized in the Q4 quartile for both Infectious Diseases and Medical Microbiology, it continues to strive for excellence and relevance in a rapidly evolving field. By facilitating open access to impactful articles (note: Open Access not applicable), the journal aims to enhance global understanding and management of infectious diseases, ensuring that practitioners are well-equipped to confront contemporary challenges in this critical area of public health. Situated in the United States at TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103, INFECTIOUS DISEASES IN CLINICAL PRACTICE plays an essential role in fostering academic discourse and advancing clinical knowledge.

Current Infectious Disease Reports, published by SPRINGER, is a leading journal dedicated to advancing knowledge in the field of infectious diseases. With an ISSN of 1523-3847 and an E-ISSN of 1534-3146, this peer-reviewed journal has established itself as a vital resource for researchers and healthcare professionals since its inception in 1999. The journal's impact in the academic community is underscored by its Q1 ranking in Infectious Diseases for 2023, placing it in the top quartile of influential journals in the field. Furthermore, it holds a respectable position at rank #95 out of 344 in the Scopus database, reflecting its substantial contribution to medicine and public health. While currently not an open access journal, it offers a wealth of articles covering the latest research, case studies, and reviews, making it an indispensable tool for those aiming to stay at the forefront of infectious disease science. As we navigate an era marked by emerging and re-emerging infectious threats, Current Infectious Disease Reports remains committed to providing high-quality, relevant research that supports evidence-based practice and informs future studies globally.

mBio is a premier, peer-reviewed open-access journal published by the American Society for Microbiology, dedicated to advancing the field of microbiology and virology. With an impressive impact factor and a commendable standing within the top quartiles (Q1) of both microbiology and virology categories as of 2023, mBio offers a dynamic platform for researchers and professionals to disseminate high-quality, rigorous scientific findings. Since its inception in 2010, it has served as a vital resource for the global scientific community, facilitating open access to groundbreaking research that spans diverse topics within microbiology. With a Scopus ranking of #28 out of 182 in Microbiology and #16 out of 80 in Virology, mBio significantly influences ongoing research trends and informs best practices in the field. Its commitment to open-access publishing allows for widespread visibility and accessibility, ensuring that critical discoveries reach a broad audience, including students and academics eager to contribute to, and learn from, cutting-edge science.

New Microbiologica is a prominent academic journal published by EDIZIONI INT SRL, dedicated to advancing knowledge in the fields of Microbiology and Medicine. Since its inception in 1993, this journal has played a vital role in disseminating cutting-edge research, featuring articles that explore the intricate relationships between microorganisms and human health. With an H-index indicating a robust citation profile and a respectable 2023 Scopus Ranking placing it in the 32nd percentile for medicine microbiology, New Microbiologica resonates well within the academic community. Although not an Open Access journal, it is strategically positioned in Quartile 3 of both Medicine (miscellaneous) and Medical Microbiology categories, which reflects its importance to researchers and professionals seeking valuable insights in their fields. Published in Italy, the journal continues to provide a platform for impactful research through its commitment to high-quality publications, fostering collaboration and innovation among scientists and academics in the ever-evolving landscape of microbiological studies.

JOURNAL OF INFECTION AND CHEMOTHERAPY, published by Elsevier, is a leading journal in the fields of Infectious Diseases, Microbiology, and Pharmacology. With a solid reputation reflected in its prestigious Q2 ranking in Infectious Diseases and Pharmacology, and Q3 in Microbiology (medical), this journal serves as a vital resource for researchers, clinicians, and students interested in the latest advancements in the diagnosis, treatment, and prevention of infectious diseases. The journal provides a platform for high-quality, peer-reviewed scholarly articles, making it an essential reference point in the medical community. Despite being published without open access, it continues to attract significant scholarly attention, as denoted by its rankings in Scopus, which showcases its impact within the academic landscape. With a timeline converging from 1995 to 2024, JOURNAL OF INFECTION AND CHEMOTHERAPY is dedicated to advancing knowledge and contributing to better health outcomes globally.